GlassScriptPhysician profile
Meredith L Staton
NPI 1841328101
$14,348.11
in general payments reported to CMS, 2019-2025
65 companies · $3,131 in 2025
The $3,131 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,088 · 2022: $2,759 · 2023: $3,076 · 2024: $3,294 · 2025: $3,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,941 · Long Term Medical Supply Or Device Loan: $1,799 · Education: $761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,941.49 |
| Long Term Medical Supply Or Device Loan | $1,799.04 |
| Education | $760.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,853.39 | 2021-2025 | |
| Janssen Biotech, INC. | $628.06 | 2021-2025 | Erleada, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $597.38 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $574.35 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Glaxosmithkline, LLC. | $567.25 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Seagen INC. | $548.32 | 2021-2025 | Adcetris, Tukysa, Tivdak |
| Daiichi Sankyo INC. | $497.44 | 2021-2025 | Enhertu |
| Celgene Corporation | $477.40 | 2021-2025 | Reblozyl, Pomalyst |
| Bayer Healthcare Pharmaceuticals INC. | $475.47 | 2021-2025 | |
| Pfizer INC. | $465.66 | 2021-2025 | |
| Gilead Sciences, INC. | $447.56 | 2022-2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $427.95 | 2021-2023 | Imbruvica, Epkinly |
| Genentech USA, INC. | $396.74 | 2021-2025 | Polivy, Lunsumio, Columvi |
| Abbvie INC. | $375.02 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $332.80 | 2021-2025 | Iclusig, Ninlaro, Fruzaqla |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $326.33 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $322.04 | 2021-2025 | Enhertu, Calquence, Lynparza |
| Stemline Therapeutics INC. | $254.44 | 2023-2025 | Orserdu |
| Lilly USA, LLC | $248.94 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Regeneron Healthcare Solutions, INC. | $238.72 | 2021-2025 | Libtayo |
| Aveo Pharmaceuticals, INC. | $237.01 | 2021-2025 | |
| Sobi, INC | $208.83 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $197.76 | 2021-2024 | |
| Amgen INC. | $195.54 | 2021-2023 | Nplate, Vectibix, Xgeva |
| Eisai INC. | $191.58 | 2021-2024 | |
| Adaptive Biotechnologies Corporation | $174.65 | 2022-2025 | Clonoseq |
| Beigene USA, INC. | $154.87 | 2023-2025 | Brukinsa |
| Puma Biotechnology, INC. | $139.35 | 2021-2025 | Nerlynx |
| Blueprint Medicines Corporation | $137.21 | 2021-2025 | Ayvakit |
| Karyopharm Therapeutics INC. | $137.19 | 2022-2024 | Xpovio |
| Exelixis INC. | $124.92 | 2021-2024 | Cabometyx |
| Pharmaessentia USA Corporation | $120.01 | 2024-2025 | Besremi |
| Rigel Pharmaceuticals, INC. | $115.88 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Deciphera Pharmaceuticals INC. | $93.17 | 2021-2025 | Qinlock, Romvimza |
| E.R. Squibb & Sons, L.L.C. | $90.62 | 2022 | |
| Servier Pharmaceuticals LLC | $89.75 | 2021-2024 | |
| Epizyme, INC. | $84.15 | 2021-2022 | |
| Morphosys, US INC. | $59.13 | 2021-2023 | Monjuvi |
| Tersera Therapeutics LLC | $57.71 | 2022 | |
| Adc Therapeutics America, INC. | $54.11 | 2024-2025 | |
| Geron Corporation | $48.90 | 2025 | Rytelo |
| Ipsen Biopharmaceuticals, INC | $41.28 | 2024 | Onivyde |
| Novocure INC. | $39.59 | 2021-2022 | |
| Cti Biopharma Corp. | $39.54 | 2023 | Vonjo |
| Astellas Pharma US INC | $38.08 | 2021-2023 | |
| Coherus Oncology, INC. | $37.14 | 2023 | |
| Mirati Therapeutics, INC. | $34.83 | 2024 | Krazati |
| Delcath Systems | $26.47 | 2025 | Hepzato Kit |
| Janssen Scientific Affairs, LLC | $26.19 | 2023 | Darzalex |
| Dendreon Pharmaceuticals LLC | $26.14 | 2025 | Provenge |
| Array Biopharma INC | $24.87 | 2021-2025 | Mektovi, Braftovi, Tukysa |
| Pharmacosmos Therapeutics INC. | $23.07 | 2024 | Cosela |
| Acrotech Biopharma INC. | $22.91 | 2024 | Beleodaq |
| Corcept Therapeutics | $21.10 | 2025 | Korlym |
| Beone Medicines USA, INC. | $20.67 | 2025 | Brukinsa |
| Taiho Oncology, INC. | $19.79 | 2023 | |
| Legend Biotech USA INC. | $18.61 | 2024 | |
| G1 Therapeutics, INC. | $18.30 | 2023 | Cosela |
| Sun Pharmaceutical Industries INC. | $17.72 | 2025 | |
| Myovant Sciences INC. | $16.45 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.70 | 2025 | Erleada |
| Kite Pharma, INC. | $14.12 | 2023 | Yescarta |
| Spectrum Pharmaceuticals INC. | $13.25 | 2023 | Rolvedon |
| Acceleron Pharma, INC. | $13.07 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Staton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.